The daily walking distance of young doctors and their body mass index.

CONTEXT: Non-exercise physical activity thermogenesis (NEAT) has been shown to differ in obese and non-obese subjects. OBJECTIVE: To explore whether NEAT is determined by the body mass index (BMI) even within the normal range, we hypothesized that the daily walking distance of young doctors in training at a teaching hospital is inversely correlated with the BMI. DESIGN: Prospective, single blind, controlled trial. SETTING: Identical wards of a 400 bed university-based teaching hospital, highly standardized for patient number treated, the severity of disease, the clinical experience of the doctors and their time spent in the institution. INTERVENTION: The walking distance was measured daily by a pedometer over one week and standardized for the setting, workload, and insurance status. MAIN OUTCOME MEASURES: Mean daily walking distance as a measure of NEAT. RESULTS: The mean daily distance walked was 2323+/-627 m with a more than 4-fold difference between the daily maximum of 4310 m and the minimum of 1003 m. There was an inverse correlation of the walking distance with the BMI (Spearman rho=0.750, p=0.02), and with the time spent in the hospital (rho=-0.800, p=0.01), but not with the months of clinical experience, age, gender, number of patients, disease, severity nor with the insurance status of the patients cared for. There was no mean difference between the distance walked in the morning vs. in the afternoon nor was there a trend from Monday through Friday. CONCLUSION: The results of this pilot study indicate that NEAT is related to the BMI in the non-obese stage.

Efficacy of homeopathically potentized antimony on blood coagulation. A randomized placebo controlled crossover trial.

BACKGROUND: Homeopathically potentized antimony 6x is traditionally used in anthroposophic medicine for an alleged pro-coagulatory effect in bleeding disorders. However, the scientific evidence base is yet insufficient. Results of a previous in vitro study suggested a slight increase of maximal clot firmness (MCF) and a tendency towards a shorter clotting time (CT). The objective of this study was to investigate the pro-coagulatory effects of antimony in vivo, and possible unexpected or adverse events. PARTICIPANTS AND METHODS: A randomized placebo controlled double blind crossover study was carried out in 30 healthy volunteers (15 males, 15 females). Each participant received intravenously 10 ml of antimony 6x and placebo in a randomized order at an interval of 1 month. Thrombelastography (TEG) was carried out immediately before and 30 and 60 min after the injection. RESULTS: Statistically significant pro-coagulatory effects were observed 30 min after injection for CT in men (p = 0.0306), and for MCF in men and women combined (p = 0.0476). The effect of antimony was significantly larger on test day 1 than on test day 2, whereas the effect of placebo was similar on both test days. No unexpected adverse or adverse events causally related to antimony were observed. CONCLUSION: This study adds evidence to the hypothesis that homeopathically potentized antimony may be efficacious in vivo. The consistency of the results with previous in vitro results indicates an effect on MCF and CT. The in vivo application of antimony 6x is safe.

Evaluation of the Orssengo-Pye IOP corrective algorithm in LASIK patients with thick corneas.

BACKGROUND: The objective of this study was to evaluate the Orssengo-Pye central corneal thickness (CCT) Goldmann applanation tonometry (GAT) corrective algorithm by observing changes in GAT and CCT before and after laser in situ keratomileusis (LASIK) surgery in patients with CCT that remains greater than 545 microm postoperatively. METHODS: Tonometric and pachymetric measurements were made on 14 patients (28 eyes) before and after LASIK surgery. The selected patients were required to have average or above average postoperative central corneal thickness values in both eyes (not less than 545 microm). Preoperatively, all patients had CCT and GAT measurements taken. Postoperatively patients had CCT, GAT, and dynamic contour tonometric (DCT) measurements taken. RESULTS: Preoperatively, median CCT values were 589.536 microm. Median GAT values were 16.750 mmHg. Median corrected preoperative GAT values were 14.450 mmHg. After LASIK treatment, median CCT values were 559.417 microm. The decrease in median CCT was 30.119 microm. Median postoperative GAT values were 11.500 mmHg (decrease, 5.250 mmHg). Median corrected postoperative GAT values were 10.775 mmHg (decrease, 3.675 mmHg). Median postoperative DCT values were 17.858 mmHg. CONCLUSIONS: LASIK treatment causes a significant reduction in measured GAT intraocular pressure (IOP) values. The Orssengo-Pye formula, which attempts to correct for GAT error associated with individual variation in CCT, appears to yield misleading results in these circumstances. An unexpected 3.675-mmHg decrease in "corrected IOP" by the Orssengo-Pye method seen in this study may be attributed to some limitation or error in the formula. After adjusting for the approximate1.7-mmHg difference, which has been demonstrated between DCT and GAT, postoperative DCT values were similar to preoperative measured GAT values.

Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.

GOALS OF WORK: The aim of this study was to evaluate the occurrence of chemotherapy-induced nausea and vomiting (CINV) and its effect on patients' ability to carry out daily life activities following moderately to highly emetogenic, first-cycle chemotherapy in routine practice in cancer centers of four different European countries. PATIENTS AND METHODS: This was a prospective, cross-sectional, nonrandomized, self-assessment study in 249 patients enrolled from cancer centers in Spain, Austria, Germany, and Switzerland. The study population consisted of 78% women, with a mean age of 54. Breast, lung, and ovarian cancers made up 75% of all cancers in the study. Patients received a mean of 2.0 chemotherapy agents and 2.5 antiemetic drugs. MAIN RESULTS: A total of 450 emetic episodes experienced by 243 patients was recorded over 5 days following chemotherapy, with an average of 1.8 episodes per patient (range: 0-28). A higher percentage of patients (38%) suffered from delayed compared to acute emesis (13%). Between 42% and 52% of all patients suffered from nausea (visual analogue scale > or = 5 mm) on any one day, peaking at day 3. Using the Functional Living Index for Emesis (FLIE) questionnaire, 75% of patients with nausea and 50% with vomiting reported a negative impact of these conditions on performance of daily living. CONCLUSIONS: CINV remains a significant problem in routine practice, particularly in the delayed phase posttreatment. Overall, CINV had a negative impact on patients' daily life.